Select a Region North America

Expertise

Lindsey Starkman

Associate Manager, Market Access and Pricing

Expertise:

医療経済およびアウトカムリサーチ (HEOR)

Lindsey is an Associate Manager, Market Access and Pricing on the Value & Evidence Team at EVERSANA. Since joining the EVERSANA team, she has leveraged her knowledge on the Canadian reimbursement landscape, navigating the complex terrain of market dynamics, reimbursement strategies and HTA frameworks. She supports in the development of Canadian Health Technology Assessment submissions as well as private insurer submissions ensuring optimal market positioning and sustainable access for clients. She works across different disease areas such as oncology, immunology, neurology, and rare disease. She is passionate about achieving success for new pharmaceuticals and communicating the value of new medical technologies.

Prior to working at EVERSANA, she worked in product development and quality assurance in the natural health product space, with a keen interest in health economics.

Articles by Lindsey Starkman

Cutting-edge Insights from EVERSANA's Global Value & Evidence Team
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC

Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques, tumor genotyping has led to the identification of actionable driver alterations in NSCLC. The ROS1 gene encodes a tyrosine kinase receptor that plays an important role in the activation of several signaling pathways associated with cellular differentiation, proliferation, growth and survival. ROS1 gene rearrangement is rare and is detected as an oncogenic driver in 0.9% to 2.6% of NSCLC cases. Crizotinib was first approved for ROS1 advanced NSCLC (aNSCLC) in the United States in […]

Interested in scheduling a meeting or speaking event?

お問い合わせ